Dr.
Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium
Shannen Deconinck has obtained her PhD in Biochemistry/biotechnology at KU Leuven Campus Kulak, Kortrijk. She worked on the development of a novel therapy to treat the acquired von Willebrand syndrome in patients with a left ventricular assist device in the Laboratory for Thrombosis Research under the supervision of Prof. Dr. Karen Vanhoorelbeke. The therapy focusses on the inhibition of ADAMTS13 using an antibody that targets the active site of the enzyme. During her thesis, both in vitro and preclinical in vivo proof-of-concept was achieved. She now continues her research activities as a post-doc in the Laboratory for Thrombosis Research where she further focusses on the valorization of the therapy to treat bleeding in LVAD patients. Shannen has already presented her work at several national and international congresses.
Sunday, July 10, 2022
8:00 AM – 9:15 AM
Tuesday, July 12, 2022
6:30 PM – 7:30 PM